Profound Medical (PROF) announces the Mount Sinai Hospital has successfully treated its first prostate cancer patient with the TULSA-PRO system. “With this milestone, Mount Sinai continues to establish itself as a leader in robotic surgical care, becoming the first health system in the New York Metro Area to offer the innovative, AI-driven, MRI-guided, and incision-free TULSA Procedure to prostate disease patients,” said Arun Menawat, Profound’s CEO and Chairman.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical Exceeds 2025 TULSA-PRO Installation Target and Grows Sales Pipeline
- Profound Medical surpasses 2025 TULSA-PRO installed base goal
- Profound Medical price target raised to $12 from $11 at Lake Street
- Profound Medical’s TULSA-PRO Marks First Commercial Case at Johns Hopkins
- Profound Medical says Johns Hopkins treats first commercial TULSA-PRO case